A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine

COVID-19 Clinical Trial

Official title:

A Phase I, Open-label Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 Vaccine in Healthy Adult Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04545749
• Other study ID #: V-122
• Status: Completed
• Phase: Phase 1
• Start date: September 25, 2020
• Est. completion date: May 24, 2021

Study information

• Verified date: February 2022
• Source: United Biomedical Inc., Asia
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase I, open-label, dose-escalation clinical study to evaluate the safety, tolerability and immunogenicity of 3 ascending doses of UB-612 COVID-19 vaccine in healthy adults, aged from 20 to 55 years old.

Description:

This is a phase I, open-label, dose-escalation clinical study to evaluate the safety, tolerability and immunogenicity of 3 ascending doses of UB-612 COVID-19 vaccine in healthy adults. Up to 60 subjects (20 subjects per group) will be enrolled into this study. Subjects in each group will be enrolled to receive two doses of UB-612 vaccine at 28-day interval (Day 0 and Day 28).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: May 24, 2021
• Est. primary completion date: January 18, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years to 55 Years

Eligibility

Inclusion Criteria:

1. Healthy male or non-pregnant female between the age of 20 and 55 years at time of enrollment.

2. Women of childbearing potential and men must agree to practice medically effective contraception from first vaccination until 3 months after the last vaccination.

3. Able to understand the content and possible risks of informed consent and willing to sign the Informed Consent Form (ICF).

4. Able to understand and agrees to comply with all study procedures and be available for all study visits.

5. Negative serological test for Hepatitis B surface antigen (HBsAg), HCV RNA and HIV antibody screening.

6. Negative in serum antibodies (IgG) against SARS-CoV-2 ELISA.

7. Negative result of RT-PCR screening of nasopharyngeal or throat swabs for SARS-CoV-2.

8. Ear temperature = 38.0°C.

9. The body mass index (BMI) of 18-30 kg/m2, inclusive, at screening.

10. Indexes of blood routine, biochemistry and other laboratory tests are within the normal ranges, or not clinically significant as judged by investigators.

11. Judged to be healthy by the investigator on the basis of medical history, physical examination, 12-lead ECG, vital signs, and clinical laboratory tests performed at screening.

Exclusion Criteria:

1. History of anaphylaxis, urticarial, or other significant adverse reaction requiring medical intervention after receipt of a vaccine.

2. Female who is pregnant or positive in pregnancy test at screening or just prior to each vaccination administration.

3. Female who is breast-feeding or plans to breastfeed from the time of the first vaccination through 60 days after the last vaccination.

4. Any acute illness, as determined by the study investigator 3 days before first vaccination.

5. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease.

6. Known history of SARS or MERS.

7. Previous exposure to SARS-CoV-2 or receipt of an investigational vaccine product for the prevention of COVID-19, MERS or SARS.

8. Subjects who take part in another clinical study within 12 weeks prior to the day of informed consent.

9. With certain underlying medical conditions which are at increased risk for severe illness from COVID-19.

10. Congenital or acquired angioedema.

11. Immune deficiency/disorder, whether due to genetic defect, immunodeficiency disease or immunosuppressive therapy.

12. Platelet disorder or other bleeding disorder may cause injection contraindication.

13. Prior chronic administration of immunosuppressant or corticosteroids, cytotoxic treatment in last 6 months before first vaccination.

14. Prior administration of immunoglobulins and/or any blood products in last 4 months before first vaccination.

15. Prior administration of attenuated, nucleic acid (mRNA or DNA) or vectored vaccines in last 1 month before first vaccination or expectation of such vaccines in the month after the second vaccination.

16. Prior administration of subunit vaccine or inactivated vaccine in last 14 days before first vaccination or expectation of receipt of such vaccines in the 14 days after the second vaccination.

17. Current anti-tuberculosis (TB) therapy or history of TB.

18. Alcoholism or substance abuser.

19. History of malignancy within 5 years prior to screening visit, except basal cell carcinoma of the skin and cervical carcinoma in situ.

20. Any medical disease or condition that, in the opinion of the study investigator, may confound the results of the study or pose an additional risk to the subjects by their participation in the study.

Related Conditions & MeSH terms

• COVID-19

Intervention

Biological:
• UB-612
UB-612 is a proprietary high-precision designer S1-RBD-protein based vaccine incorporating a Th/CTL epitope peptide pool which could bind to human MHC-I and MHC-II to activate T cells.

Locations

Country	Name	City	State
Taiwan	China Medical University Hospital	Taichung

Sponsors (2)

Lead Sponsor	Collaborator
United Biomedical Inc., Asia	Vaxxinity, Inc.

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety of UB-612 vaccine	Occurrence of adverse reactions within 7 days after vaccination; Percentage of subjects with = Grade 3 adverse events within 7 days after vaccination	7 days following vaccination
Secondary	Safety	Occurrence of adverse events (AEs) till Day 56; Occurrence of serious adverse events (SAEs) till Day 56	Day 0 to Day 56
Secondary	Safety	Occurrence of serious adverse events during the whole follow-up period	Day 29 to Day 196
Secondary	Safety	Occurrence of adverse events of special interest during the study period	Day 0 to Day 196
Secondary	Immunogenicity	Geometric mean titer (GMT) of antigen-specific antibody (Anti-S1-RBD)	Day 14, 28, 42, 56, 112, and 196
Secondary	Immunogenicity	Seroconversion rate (SCR) of antigen-specific antibody (Anti-S1-RBD)	Day 14, 28, 42, 56, 112, and 196
Secondary	Immunogenicity	Geometric mean fold increase of antigen-specific antibody (Anti-S1-RBD)	Day 14, 28, 42, 56, 112, and 196